PWM
JAZZ icon

Parkworth Wealth Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Parkworth Wealth Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$212 Hold
2
– – ﹤0.01% 932
2025
Q1 		$248 Hold
2
– – ﹤0.01% 656
2024
Q4 		$246 Buy
+2
New +$236 ﹤0.01% 685

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Parkworth Wealth Management's JAZZ Position: Q2 2025 in Review

Parkworth Wealth Management held its Jazz Pharmaceuticals (JAZZ) position steady in Q2 2025 at 2 shares worth $212. The position accounts for ﹤0.01% of the portfolio, ranked #932.

Parkworth Wealth Management first reported a position in JAZZ in Q4 2024 and has held it in 3 quarters since. The position peaked at $248 in Q1 2025. 501 funds tracked by Wall St. Rank hold JAZZ as of Q2 2025.

  • Parkworth Wealth Management held 2 shares of Jazz Pharmaceuticals worth $212 as of Q2 2025.
  • Parkworth Wealth Management left its Jazz Pharmaceuticals share count unchanged in Q2 2025.
  • Jazz Pharmaceuticals made up ﹤0.01% of Parkworth Wealth Management's portfolio in Q2 2025, its #932 holding.
  • Parkworth Wealth Management first reported a position in Jazz Pharmaceuticals in Q4 2024 and has held it in 3 quarters since.
  • Parkworth Wealth Management's Jazz Pharmaceuticals position peaked at $248 in Q1 2025.
  • 501 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2025.

Based on Parkworth Wealth Management's 13F filing for Q2 2025, filed 13 Aug 2025.